When does the afatinib patent expire?
Patent expiry dates depend on the country and on which specific patent in the drug’s patent “family” is being referenced. For afatinib (Gilotrif), companies and generic entrants typically look at a mix of compound, formulation, and method-of-use patents across multiple jurisdictions, so the last-expiring patent in each market can differ.
Why do different sources give different expiry dates?
For branded medicines like afatinib, the “expiry” date you see online may refer to one of several distinct milestones:
- the end of the compound patent term,
- the end of a secondary patent (formulation, dosing regimen, combinations),
- the end of data exclusivity (regulatory protection of clinical data),
- or the first date generics can sell a product after launch approval.
Which one a source reports (and which jurisdiction) can change the date by years.
Can generics enter before the last afatinib patent expires?
Often, yes, but “entry” can mean different things:
- A generic may receive regulatory approval at one time but face marketing limits if patents are still in force.
- A generic company might launch “at risk” once it believes patents are invalid or not infringed, which can trigger patent litigation.
- Some countries also allow limited marketing earlier via specific regulatory pathways, even if full commercial entry is delayed.
What markets usually matter for afatinib patent expiry?
Most generic-patent timelines turn on major markets where regulatory approval and sales are significant, including the US, Europe (and individual EU member states), the UK, and Japan. Each uses its own patent term adjustments and exclusivity rules, which is why the effective expiry can differ.
How to check the exact afatinib patent expiry for your country
To get a precise date, you normally need:
- the jurisdiction (e.g., US vs Germany vs Japan),
- the branded product name used in that market,
- and the specific patent(s) listed in that country’s patent register or court filings.
If you tell me the country (and whether you want marketing approval vs full commercial launch), I can narrow the search-intent to the relevant expiry type and jurisdiction.
Are there any known legal or “evergreening” issues with afatinib?
Brand holders sometimes rely on later-filed patents to extend exclusivity beyond the original compound patent. That can lead to patent disputes when generic applicants challenge either patent validity or infringement. As a result, the practical date when generics can sell often depends on litigation outcomes, not just the nominal patent term.
What is the difference between patent expiry and data exclusivity for afatinib?
Even after patent expiry, some protection tied to regulatory data can keep competitors from relying on the originator’s dossier. Patent expiry affects infringement, while data exclusivity affects regulatory reliance. The earliest possible generic market entry typically requires both infringement clearance (or expiry) and regulatory ability to reference data under local rules.
If you want the exact date, what should you provide?
Share:
1) the country (or countries),
2) whether you mean first possible generic approval or first generic sales, and
3) the brand name you’re tracking (e.g., Gilotrif).
With that, the expiry answer can be pinned to the relevant patents and the correct exclusivity milestone.